Packing drug Zometa.
 Zometa - synthetic drug used in the treatment of bone metastases of malignant tumors spread.

Pharmacological action

Active substance Zometa has selective effect on bone resorption and inhibits bone tissue and also has anti-cancer properties that provide efficacy in bone metastases. Thus Zometa no adverse effect on mineralization, formation and mechanical properties of bone.

By responses Zometa prevents compression of the spinal cord and the development of pathological fractures, in turn, reduces the need for radiation therapy and surgery.

Product form

Zometa is produced in the form of a concentrate for solution for infusion in 5 ml vials containing 4 mg zoledronic acid.

For analogs include drugs Zometa Aklasta, Blaztera, Veroklast, Veroklast, Zoleriks, Rezoklastin FS Rezorba, Zoledronic acid-Teva, Zoledreks.

Indications for use of Zometa

According to the instructions Zometa is indicated for the treatment of:

  • Bone metastases common malignant tumors and multiple myeloma and also for reducing the risk of spinal cord compression, pathological fractures and hypercalcemia, are caused by a tumor;
  • Hypercalcaemia caused by malignant tumor.


Zometa is contraindicated according to the instructions to apply at:

  • Pregnancy;
  • Lactation;
  • Hypersensitivity to bisphosphonates and other ingredients.

How to use Zometa

 The drug Zometa for solution for infusion.
 The recommended dose of Zometa when bone metastases common malignant tumors and multiple myeloma for adults is 4 mg. The drug is administered intravenously. Zometa is used according to instructions every 3-4 weeks. Simultaneously with the preparation additionally administered vitamin D.

When hypercalcemia which is due to cancer, the recommended dose is 4 mg also, the solution is recommended to be administered simultaneously with saline to ensure adequate hydration.

Typically, the solution for infusion is prepared from one Zometa vials, to be diluted in 100 mL of the calcium-containing solution for infusion. Store the resulting solution may be less than a day. In the preparation of Zometa should not be confused with any other drugs, and the introduction of a separate system must be used for intravenous infusions.

If overdose or Zometa counterparts, often marked renal dysfunction and changes in the composition of the electrolyte.

Side effects

Judging by the reviews Zometa often causes anemia, headache, bone pain, myalgia, conjunctivitis, arthralgia, renal dysfunction, generalized pain, fever, flu-like symptoms, including chills, fever and malaise.

Less use of the drug and analogs Zometa may cause:

  • Thrombocytopenia;
  • Muscle cramps;
  • Hypoesthesia;
  • Cough;
  • Paresthesia;
  • Dysgeusia;
  • Shortness of breath;
  • Peripheral edema;
  • Hematuria;
  • Leukopenia;
  • Dizziness;
  • Hyperesthesia;
  • Tremors and anxiety;
  • Sleep disorders;
  • Weight gain;
  • Itching and rash;
  • Excessive sweating;
  • Acute renal failure;
  • Proteinuria;
  • Asthenia;
  • Chest pain.

Pancytopenia, episcleritis, confusion, uveitis, bradycardia, angioedema develop while taking Zometa on responses rarely.

Storage conditions

Zometa belongs to a number of prescription drugs with a shelf life of 3 years.